Tevogen Bio Holdings Inc. (TVGN)
Nasdaq: TVGN · Biological Products, (No Diagnostic Substances) · Warren, NJ · filing with the SEC since 2021
Who owns Tevogen Bio Holdings Inc.
As filed with the SECHolders of 5% or more
2
Saadi Ryan H. holds 74.4% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13D/A filed Sep 16, 2026 says.
Directors and officers
8
report now, of 22 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Saadi Ryan H.
SCHEDULE 13D/A · filed Sep 16, 2026 · Common Stock, par value $0.0001 per share · 59.7% in Jul 14, 2026
Kirti Desai
SCHEDULE 13D/A · filed Sep 16, 2026 · Common Stock, par value $0.0001 per share
What TVGN reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 31, 2026.
Insider tradesForm 4
3sales
0purchases
0sales on a scheduled plan
1people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 4, 2025 to Nov 4, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 4, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window1 of 27 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Flomenberg Neal | Chief Scientific Officer, Global R&D Lead. All holdings herein have been adjusted to reflect the Company's 1-for-50 reverse stock split eff | 3 | $0 | 0 | 0 | $0 |